The Trump administration had an opening. The hemp market proved the concept. The polling supported the move. The fiscal argument was there. Instead, the White House published a 195-page document that reads like it was written in 1988, invokes psychosis studies with contested methodology, and affirms the recriminalization of a $28 billion industry that was, by any reasonable measure, working.

Start with the most obvious one. The pharmaceutical industry loses, by some estimates, around $10 billion annually in markets where medical cannabis is legal. Patients substitute cannabis for opioids, sleep aids, anti-anxiety medications, and antidepressants. Not all patients, and not always — but enough to show up in the revenue reports.

The 2026 awards made one thing clear: growers are done with mystery clones from anonymous sellers. Get Seeds Right Here earned #1 because it gave growers the strongest overall package: catalog, reputation, ordering experience, and a clear long-term commitment to the cannabis clone space. The rest of the top five earned their spots doing the same work at a slightly smaller scale.

This is the legacy knowledge drain, and it is the quiet catastrophe nobody in the cannabis industry wants to talk about openly—because acknowledging it means acknowledging that the "professionalization" of weed has, in many respects, destroyed the thing that made it worth professionalizing.

The petrochemical industry that grew in hemp's absence now generates revenues in the tens of trillions annually across its downstream product chains—plastics, synthetic fibers, lubricants, paints, solvents, packaging, insulation, construction materials.

Every two years, cannabis advocates wheel out the same ritual. Ballot measures, candidate endorsements, grasstops lobbying, NORML scorecards, press releases about historic progress. Every two years, a version of the same headline runs: "Cannabis Reform Reaches Tipping Point." Every two years, the people who believed it discover that the tipping point was a marketing event.

This makes us now ponder if the future of the marijuana industry will be handed over to Big Cannabis, as this move may capitalize on a huge financial shift (possibly the biggest one we’ve ever seen): quite possibly, it could signal the end of the 280E tax laws due to Schedule III reform.

That is a fair question. The 7OH market can be confusing, especially with so many tablets, shots, gummies, powders, Pseudo products, MIT products, MGM-15 products, and specialty alkaloid blends available online. Product names can sound similar, strengths can vary widely, and shoppers need more than flashy packaging to make a confident decision.

White House Press Secretary Karoline Leavitt described the rescheduling as something the president did 'at the behest of the American public, who largely support it.' That framing deserves scrutiny. The American public largely supports full federal legalization. They were given partial medical rescheduling. These are not the same thing, and the study makes that impossible to misread.

Here is where it breaks down. Section 2 of the application — the Activity section — asks applicants to specify which substances they handle. One of those questions asks whether your firm will be handling or dispensing recreational marijuana. If you answer yes, you are, by the federal government's own definition, admitting to trafficking a Schedule I controlled substance. On a federal form. With your name, address, Social Security number, and Tax ID attached.